Geneva, Switzerland — November 28, 2022
Medimaps — the creator of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and digital health executive with 25+ years of experience, has been named Board Chairman. Anne Le Grand, an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member.
Five additional board members and one board advisor have also been named, bolstering Medimaps Group’s investment and clinical policy expertise.
“I'm pleased to welcome Meinhard and Anne to our Board of Directors. Meinhard's global leadership roles in diagnostics at Philips and Roche Diagnostics, and Anne's work leading medical imaging and healthcare businesses including AI solutions, offer Medimaps significant expertise and acumen to support our immediate growth and shape our future success.
said Didier Hans, CEO and Co-founder of Medimaps.
About the appointees
Mr. Schmidt held senior leadership roles at Philips and Roche Diagnostics, spanning Patient/Diabetes Care and Laboratory and Point-of-Care Diagnostics. He went on to serve as an executive at Institut Straumann, first as a Business Unit head and later as CEO, where he led the digital group responsible for worldwide digitalization of the dental industry. He currently holds board and advisory roles for public and private MedTech/digital health companies, focusing on growth and commercialization.
Ms. Le Grand served as Global Vice President and General Manager for IBM Watson Health Imaging, Oncology, Genomics and Life Sciences. Prior to IBM, she held executive leadership positions at Philips Health Systems, leading the Therapeutic Care and Ultrasound divisions, and previously served as SVP Healthcare of Global X-ray for GE Healthcare, where she launched and refreshed portfolios across the global X-ray, mammography, and metabolic bone disease businesses. She currently holds board and consulting roles for public and private sector healthcare companies.
Additional board members include
Robert Schier, PhD, Senior Investment Director at Zürcher Kantonalbank Asset Management (Swisscanto Private Equity). Dr. Schier sits on the boards of directors of numerous life sciences companies. He holds a degree in pharmacy from the University of Vienna and a PhD in biotechnology from the University of Natural Resources and Life Sciences, Vienna.
– **Myoung-Ok Kwon, PhD**, investment partner at Swisscom, leading digital health investments. She has 20 years of experience in healthcare investment and pharma research, and previously led research strategy and portfolio review at Novartis. She holds a PhD in biochemistry and molecular genetics from the Friedrich Miescher Institute, Novartis, and the University of Basel.
– **Georgette Schmid**, investment manager at Helvetica Capital AG. Prior to joining Helvetica Capital, Ms. Schmid worked in business development and investment within the consumer goods and hotel industries. She holds a Master of Law from the University of Zurich and an MBA from Ecole hôtelière de Lausanne.
– **Prof. Didier Hans, PhD, MBA**, CEO of Medimaps Group since 2012. He has 25+ years of experience in dual-energy X-ray absorptiometry (DXA), bone macro- and microarchitecture, ultrasound imaging techniques, and body composition assessment, and teaches worldwide on bone and body composition imaging and osteoporosis. He holds a PhD in medical physics and an Executive MBA from HEC Geneva.
– **Sarah Lumb**, co-founder and managing partner of Mission Global, a freight specialist in event logistics, which she helped build into a network of nearly 200 partner offices worldwide. Her business interests also include Ethical Pharmaceutical Consulting Service SA and Kanis SA, with investments spanning biotech, medical devices, and other high-technology industries.
– **Lauren Nicola, MD** (board advisor), CEO of Triad Radiology Associates in the US, subspecialized in breast imaging and pediatric radiology. A national health policy expert, Dr. Nicola holds leadership positions at the American College of Radiology, including chair of the Reimbursement Committee and the Medicare Access and CHIP Reauthorization Act (MACRA) Committee, and has been instrumental in the creation and valuation of multiple new imaging and AI codes. She holds a medical degree from Duke University School of Medicine.
About Medimaps
Medimaps (Medimaps Group SA) is a medtech AI company on a mission to help clinicians catch what routine imaging misses — every scan, every patient — for better care, building toward an era where healthy bones are the norm.
The creators of Trabecular Bone Score® (TBS®) — the global standard in bone microarchitecture assessment, cited in more than 35 international clinical guidelines and supported by 1,600+ peer-reviewed publications — Medimaps develops imaging software that helps clinicians see bone quality, not just bone density, and predict fracture risk from the imaging they already perform.
Following its merger with Radiobotics, an award-winning Danish MedTech company, Medimaps is building a clinical portfolio spanning the MSK care continuum — from TBS Reveal™, opportunistic bone fragility assessment from routine X-rays, to TBS Osteo™, for osteoporosis fracture risk assessment on DXA, to RBfracture™, designed to support emergency and radiology teams with detection of trauma-related findings on X-ray.
Medimaps is headquartered in Geneva, Switzerland, with offices in Denmark, France, and the US, with technology deployed in more than 90 countries. Medimaps is certified to ISO 13485:2016 and MDSAP. Learn more at medimaps.ai.
